Deep inspiration breath hold in locally advanced lung cancer radiotherapy: validation of intrafractional geometric uncertainties in the INHALE trial.


Journal

The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125

Informations de publication

Date de publication:
Dec 2019
Historique:
pubmed: 24 9 2019
medline: 28 11 2019
entrez: 24 9 2019
Statut: ppublish

Résumé

Patients with locally advanced non-small cell lung cancer (NSCLC) were included in a prospective trial for radiotherapy in deep inspiration breath hold (DIBH). We evaluated DIBH compliance and target position reproducibility. Voluntary, visually guided DIBHs were performed with optical tracking. Patients underwent three consecutive DIBH CT scans for radiotherapy planning. We evaluated the intrafractional uncertainties in the position of the peripheral tumour, lymph nodes and differential motion between them, enabling PTV margins calculation. Patients who underwent all DIBH imaging and had tumour position reproducibility <8 mm were up-front DIBH compliant. Patients who performed DIBHs throughout the treatment course were overall DIBH compliant. Clinical parameters and DIBH-related uncertainties were validated against our earlier pilot study. 69 of 88 included patients received definitive radiotherapy. 60/69 patients (87%) were up-front DIBH compliant. DIBH plan was not superior in seven patients and three lost DIBH ability during the treatment, leaving 50/69 patients (72%) overall DIBH compliant.The systematic and random errors between consecutive DIBHs were small but differed from the pilot study findings. This led to slightly different PTV margins between the two studies. DIBH compliance and reproducibility was high. Still, this validation study highlighted the necessity of designing PTV margins in larger, representative patient cohorts. We demonstrated high DIBH compliance in locally advanced NSCLC patients. DIBH does not eliminate but mitigates the target position uncertainty, which needs to be accounted for in treatment margins. Margin design should be based on data from larger representative patient groups.

Identifiants

pubmed: 31544478
doi: 10.1259/bjr.20190569
pmc: PMC6913352
doi:

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20190569

Références

Radiother Oncol. 2017 Apr;123(1):78-84
pubmed: 28245908
Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):822-34
pubmed: 12095547
Acta Oncol. 2016 Aug;55(8):1053-6
pubmed: 26935017
Acta Oncol. 2012 May;51(5):610-7
pubmed: 22263924
Br J Radiol. 2016 Dec;89(1068):20160544
pubmed: 27706950
Acta Oncol. 2013 Oct;52(7):1458-63
pubmed: 23957594
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e639-45
pubmed: 22197237
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):959-66
pubmed: 25585787
Adv Radiat Oncol. 2017 Mar 10;2(3):354-362
pubmed: 29114603
Radiother Oncol. 2015 Jul;116(1):64-9
pubmed: 26096849
Radiother Oncol. 2015 Oct;117(1):55-63
pubmed: 26385266
Cancer Invest. 2012 May;30(4):323-30
pubmed: 22489833
Med Phys. 2004 Nov;31(11):3068-79
pubmed: 15587660
Strahlenther Onkol. 2012 Jul;188(7):582-9
pubmed: 22588467
Semin Radiat Oncol. 2016 Jan;26(1):71-8
pubmed: 26617212
Radiother Oncol. 2008 Apr;87(1):65-73
pubmed: 18267345
Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):1121-35
pubmed: 10863086
Radiother Oncol. 2009 Dec;93(3):424-9
pubmed: 19854526
Radiother Oncol. 2019 Apr;133:230
pubmed: 30773227
Front Oncol. 2018 Apr 04;8:87
pubmed: 29670854
J Thorac Oncol. 2011 Dec;6(12):2058-68
pubmed: 22052228
Radiother Oncol. 2013 Jan;106(1):28-32
pubmed: 23199652
Acta Oncol. 2015 Jan;54(1):60-6
pubmed: 25025999
Radiother Oncol. 2016 Jun;119(3):432-7
pubmed: 27072938
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):910-7
pubmed: 20510201
Semin Radiat Oncol. 2004 Jan;14(1):52-64
pubmed: 14752733
Radiother Oncol. 2017 Jul;124(1):1-10
pubmed: 28666551
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):478-92
pubmed: 26867877
Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):864-74
pubmed: 14529794
Radiother Oncol. 2016 Oct;121(1):32-38
pubmed: 27647459
Radiother Oncol. 2016 Mar;118(3):510-4
pubmed: 26631647

Auteurs

Mirjana Josipovic (M)

Department of Oncology, Section of Radiotherapy, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Niels Bohr Institute, Faculty of Science, University of Copenhagen, Blegdamsvej 17, 2100 Copenhagen, Denmark.

Marianne C Aznar (MC)

Department of Oncology, Section of Radiotherapy, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Niels Bohr Institute, Faculty of Science, University of Copenhagen, Blegdamsvej 17, 2100 Copenhagen, Denmark.
Manchester Cancer Research Centre, Division of Cancer Science, University of Manchester, c/o the Christie NHS, Wilmslow Road, Manchester M20 4BX, UK.
Department of Clinical Medicine, Faculty of Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2100 Copenhagen, Denmark.

Jakob B Thomsen (JB)

Department of Oncology, Section of Radiotherapy, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Jonas Scherman (J)

Department of Oncology, Section of Radiotherapy, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Niels Bohr Institute, Faculty of Science, University of Copenhagen, Blegdamsvej 17, 2100 Copenhagen, Denmark.
Department of Hematology and Oncology Radiation Physics, Skåne University Hospital, 21185 Lund, Sweden.

Sidsel Ms Damkjaer (SM)

Department of Hematology and Oncology Radiation Physics, Skåne University Hospital, 21185 Lund, Sweden.

Lotte Nygård (L)

Department of Oncology, Section of Radiotherapy, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Lena Specht (L)

Department of Oncology, Section of Radiotherapy, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Department of Clinical Medicine, Faculty of Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2100 Copenhagen, Denmark.

Mette Pøhl (M)

Department of Oncology, Section of Radiotherapy, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark.

Gitte F Persson (GF)

Department of Oncology, Section of Radiotherapy, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, 2100 Copenhagen, Denmark.
Department of Clinical Medicine, Faculty of Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2100 Copenhagen, Denmark.
Department of Oncology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, 2730 Herlev, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH